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Abstract 
Breast cancers are potentially life-threatening malignancies in women. Development of cancer produces oxidative stress, 
which increases with disease progression. Hence, studies on antioxidants may be the most promising area of research for this 
clinical menace. We analysed serum Uric acid (UA) and Bilirubin (BR) in women with breast cancer. The changes in the levels 
of serum uric acid and bilirubin are measured in breast cancer patients to assess the oxidative stress. A significant increase in 
the levels of uric acid and an insignificant increase in the levels of bilirubin was observed in all the three categories of breast 
cancer patients compared to normal individuals. The results suggested that high ROS production supports the oxidative stress 
in breast cancer. So, the treatment with antioxidants in the initial stages of the disease may be useful as secondary therapy. 
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Introduction 
Breast cancer is one of the most common cancers 
in women of the developed and developing countries. 
Experimental investigations as well as clinical and 
epidemiological studies implicate the involvement of 
oxygen derived radicals such as singlet oxygen (1O2), 
superoxide anions (O2•¯), hydrogen peroxide (H2O2) 
and hydroxyl radical (OH•) in the etiology of cancer 
(Oberley and Oberley, 1989, Fisher et al., 1983). Free 
radicals are formed in both physiological and 
pathological conditions in mammalian tissues. In 
healthy conditions at cellular level, a subtle balance 
exists between the free radical generation and the 
antioxidant defense.  Reactive Oxygen species (ROS) 
are essential for multiple normal physiological 
processes like cell differentiation (Abe et al., 2000), 
apoptosis (Ghosh, 1998), cell immunity (Golub et al., 
1985) and cellular defense against microorganisms 
(Lajarin et al., 1999)  at low concentrations. Excess 
generation of these oxygen free radicals and oxidants 
generate a phenomenon called oxidative stress which 
cause oxidative damage to biomolecules resulting in 
lipid peroxidation, mutagenesis and carcinogenesis. 
There is accumulating evidence from animal and 
human systems implicating a role of oxidative stress 
and lipid peroxidation in the development of breast 
cancer (Mianying Wang et al., 1996). Several studies 
reported that malondialdehyde; the end product of lipid 
peroxidation can cause cross-linking in lipids, proteins 
and nucleic acids (Freeman BA 1982). It is also evident 
that overproduction of ROS/RNS (Halliwell, 1989, Kang, 
2002) plays an important role in the promotion and 
progression of human cancers, including breast cancer 
(Aghvami et al., 2006, Ray et al., 2000, Huang et al., 
1996, Yeh, 2005). The human body is equipped with 
certain enzymatic and non-enzymatic antioxidant 
systems (Faruk Tas et al., 2005, Portakal et al., 2000). 
Antioxidants are known to dispose, scavenge, and 
suppress the formation of free radicals or oppose their 
action and increase with the severity of the disease 
(Singh et al., 2003, Galleotti et al., 1991).  
The precise mechanism of the oxidative stress 
being induced in breast cancer is still not exactly 
understood and documented. Hence, in the present 
study an attempt has been made to determine the 
alteration in oxidant-antioxidant status in breast cancer 
patients, by estimating the antioxidants like Uric Acid 
and Bilirubin. 
 
Materials and Methods  
This study was conducted at Mahatma Gandhi 
Cancer and Research Institute and in the Department 
of Biochemistry, Andhra University, Visakhapatnam. 
116 clinically and histopathologically proven breast 
cancer patients were chosen for the present study. Due 
permission was obtained from the management of the 
Mahatma Gandhi Cancer and Research Institute 
before the commencement of the work. The written 
consent of the patients was also taken. An equal 
number of age matched healthy subjects were 
considered as normal/control. The complete clinical 
and personal history of the patients was recorded. The 
subjects were ranging from 30-69 years of age. 
Patients suffering from diseases of any origin other 
than breast cancer were excluded from the study.  
The study subjects are segregated into four 
groups so that the age group between 30-39 is referred 
to as group-1, followed by group-2 from40-49 years of 
age, then group-3 from 50-59 years and finally group-4 
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from the age of 60 to 69 years. The study was carried 
out in three different categories of breast cancer 
patients in different clinical conditions.   
Category I: The selected study parameters like 
uric acid and bilirubin levels were analyzed in untreated 
breast cancer patients undergoing for treatment for the 
first time.  
Each study group (age) was classified into four 
stages i.e., stage-I, II, III and IV according to 
Manchester’s classification based on a clinical 
evaluation of the patients case study. 
Category II: The study parameters were also 
monitored continuously in breast cancer patients for 
more than 2 years time at intervals of 3, 6, 12, 18 and 
24 months, irrespective of type of clinical treatment / 
age/ stage of breast cancer.  
Category III: The study parameters were also 
investigated irrespective of the patient’s age and stage 
of the cancer in 10 patients each, who were 
undergoing different types of clinical treatments like 
chemotherapy, surgical removal of breast tissue and 
radiation. 
Blood was collected by venous arm puncture in 
patients and controls. The blood collected was 
centrifuged to separate the serum, with which the 
clinical investigations for the levels of selected 
antioxidants were carried out. Uric acid was 
determined by the end point assay described by Trivedi 
et al. (1978) and  bilirubin by the method of diazotized 
sulfanilic acid by Wins ten 1969 respectively. All the 
chemicals used were of analytical grade.  
Statistical analysis between the normal individuals 
and patients was performed by the student t-test. The 
data expressed as Mean ± SD and p<0.05 were 
considered as significant. 
 
Results and Discussion 
The Mean values of Uric acid and Bilirubin for 
category I patients are indicated in the fig. 1, the mean 
and independent values for the category II patients are 
indicated in table 1 and the mean values for category 
III patients are shown in fig. 2 respectively. 
In the present study, the association of serum uric 
acid levels to oxidative stress in breast cancer patients 
is prospectively investigated. Our results strongly 
reflect against the proposed antioxidant properties and 
protective effect of serum UA on breast cancer. The 
serum UA levels in the category I patients of all age 
groups with respect to the stage has been observed to 
be prominent, which suggests a positive association 
between serum uric acid and oxidative stress. Thus UA 
contributes to increased life span in humans by 
providing protection against oxidative stress provoked 
ageing and cancer. A significant rise of serum uric acid 
levels were observed in the stages III and IV of all age 
groups as shown in fig 1. This shows the protective 
role of serum uric acid in the ageing women with breast 
cancer. In category II patients  the serum UA levels are 
insignificant compared to the untreated breast cancer 
patients, which may be due to high oxidative stress 
which may perhaps lead to the generation of a large 
number of free radicals was diminished by uric acid as 
presented in the table 1.  Serum UA levels in the 
category III subjects was observed to be slightly higher 
compared to the control (fig 2).
 








UA-Uric acid, BR-Bilirubin 
Group 1: 30-39, Group-2: 40-49, Group- 3: 50-59, Group 4: 60-69  
All the values are expressed as Mean.* p<0.05 compared to controls 
 
Table 1: Serum antioxidant levels in continuously monitored Breast cancer patients compared to normal 
 
Name of the 
Antioxidant 
Normal 3 Months 6Months 12Months 18Months 24Months 
UA   4.0 5.4 6.7 8.7 11.3 13.48 
BR 0.53 0.63 0.7 0.76 0.8 0.84 
UA-Uric acid, BR-Bilirubin 
†All the values are expressed as Mean of 6 subjects 
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Fig 2: Serum antioxidant levels in Category III breast cancer patients under different clinical treatments like surgery, chemotherapy and 










‡All the values are expressed as Mean of 10 subjects 
 
Based on the potent antioxidant properties of 
bilirubin (Jaime Kapitulnik, 2004) and the proposed role 
of oxidative stress in carcinogenesis have been 
examined for an association between serum bilirubin 
levels and stages of breast cancer. In the present study 
in category I the rate of BR increase was insignificant 
in patients compared to the control, (fig. 1) suggesting 
that bilirubin is consumed to cope with oxidative stress 
(Sedlak Thomas, 2004) and our results also correlate 
with the reports of Stephen et al. (2004) which states 
that individuals with a prior history of malignancy have 
a lower mean bilirubin levels than those without cancer 
supports the hypothesis that bilirubin suppresses 
carcinogenesis. Serum BR levels in category II patients 
was observed to be almost in the normal range (table 1) 
and showed a very low rate of increment which might 
be due to oxidative stress. In category III patients 
slightly increased levels were observed when 
compared to the control (fig. 2). 
From the above observations of our study, it is 
detected that there is an increase in the serum UA 
levels which show a higher free radical production and 
insignificant increase in the BR levels are seen. The 
increased levels of antioxidants like uric acid may be a 
compensatory regulation in response to this increased 
oxidative stress. Therefore, exogenous administration 
of antioxidants may be helpful in the management of 
breast cancer. So, the treatment with antioxidants in 
the initial stages of the disease may be useful as 
secondary therapy to prevent the oxidative damage.  
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